Drugs / LAPACHONE
LAPACHONE
also known as
ARQ 501 · MB12066 · .beta.-lapachone · Beta-lap-wj · Lapachone, beta- · NSC-26326 · NSC-629749
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02338856 | Jan → Feb 2015 | metabolic syndrome X | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01285388 | Jul 2010 → Jan 2011 | metabolic syndrome X, obesity disorder | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00524524 | Aug 2007 → Aug 2008 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00099190 | Dec 2004 → Nov 2006 | carcinoma | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00075933 | Sep 2003 → Jan 2007 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00622063 | Dec 2006 → Sep 2008 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02029586 | Jan 2013 → Nov 2014 | NAFLD1 | Yungjin Pharm. Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00358930 | Jul 2006 → Aug 2007 | head and neck neoplasm, squamous cell carcinoma | ArQule, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00310518 | Feb 2006 → Jul 2007 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00102700 | Jan 2005 → Jan 2007 | adenocarcinoma, malignant pancreatic neoplasm | ArQule, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01444677 Comparator | Apr 2011 → Apr 2012 | metabolic syndrome X, obesity disorder | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAPACHONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL15192 ↗ |
| Known as | .beta.-lapachone | ChEMBL registry synonym — accepted as the source's own label CHEMBL15192 ↗ |
| Known as | ARQ 501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00358930 ↗ |
| Known as | Beta-lap-wj | ChEMBL registry synonym — accepted as the source's own label CHEMBL15192 ↗ |
| Known as | Lapachone, beta- | ChEMBL registry synonym — accepted as the source's own label CHEMBL15192 ↗ |
| Known as | MB12066 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01444677 ↗ |
| Known as | NSC-26326 | ChEMBL registry synonym — accepted as the source's own label CHEMBL15192 ↗ |
| Known as | NSC-629749 | ChEMBL registry synonym — accepted as the source's own label CHEMBL15192 ↗ |
| Modality | Small molecule | “a fully synthetic small molecule version of β-lapachone” NCT00524524 ↗ |
| Route | Intravenous | “for intravenous (IV) administration” NCT00524524 ↗ |